Abstract:
Objective To explore the clinical efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in the consolidation treatment of elderly patients with aggressive lymphoma.
Methods A total of 80 elderly patients (age > 60 years old) with aggressive lymphoma who received consolidation treatment after remission in Gansu Wuwei Tumour Hospital from January 2019 to December 2023 were selected for the study. According to whether the patients agreed to undergo auto-HSCT, they were divided into two groups, auto-HSCT group and conventional chemotherapy group, with 40 patients in each group. The auto-HSCT group was the study group, and the conventional chemotherapy group was the control group. The efficacy and survival differences of the two groups were compared and analyzed.
Results The objective response rate and complete remission of the patients in the auto-HSCT group were 90.00% and 40.00%, respectively, which were higher than those in the conventional chemotherapy group (P < 0.05). There was no significant statistical difference in adverse reactions between the auto-HSCT group and the conventional chemotherapy group (P > 0.05). The five-year survival rate and progression-free survival of the auto-HSCT group were higher than those of the conventional chemotherapy group, and the differences were statistically significant (P < 0.05). At 6 months, 1 year, and 3 years post-treatment, FACT-Lym scores were significantly higher in the auto-HSCT group than in the conventional chemotherapy group (P < 0.05).
Conclusion Compared with traditional chemotherapy, autologous hematopoietic stem cell transplantation can help improve the efficacy and long-term survival of elderly patients with aggressive lymphoma in consolidation treatment, while demonstrating relatively high safety.
下载: